Next Century Growth Investors LLC Acquires 44,118 Shares of TransMedics Group, Inc. $TMDX

Next Century Growth Investors LLC raised its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 81.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 98,468 shares of the company’s stock after purchasing an additional 44,118 shares during the quarter. Next Century Growth Investors LLC’s holdings in TransMedics Group were worth $11,979,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Harvest Fund Management Co. Ltd bought a new stake in shares of TransMedics Group during the third quarter worth $29,000. Allworth Financial LP lifted its position in shares of TransMedics Group by 74.3% during the third quarter. Allworth Financial LP now owns 265 shares of the company’s stock worth $30,000 after purchasing an additional 113 shares during the last quarter. Optiver Holding B.V. lifted its position in shares of TransMedics Group by 248.1% during the third quarter. Optiver Holding B.V. now owns 268 shares of the company’s stock worth $30,000 after purchasing an additional 191 shares during the last quarter. Parallel Advisors LLC lifted its position in shares of TransMedics Group by 42.1% during the fourth quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock worth $34,000 after purchasing an additional 83 shares during the last quarter. Finally, LOM Asset Management Ltd bought a new stake in shares of TransMedics Group during the third quarter worth $34,000. 99.67% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts have recently weighed in on TMDX shares. Canaccord Genuity Group decreased their target price on TransMedics Group from $152.00 to $124.00 and set a “buy” rating for the company in a research report on Wednesday, May 6th. Oppenheimer downgraded TransMedics Group from an “outperform” rating to a “market perform” rating in a research report on Wednesday, May 6th. Stifel Nicolaus decreased their target price on TransMedics Group from $85.00 to $75.00 and set a “hold” rating for the company in a research report on Tuesday, May 26th. Weiss Ratings reiterated a “hold (c)” rating on shares of TransMedics Group in a research report on Tuesday. Finally, Piper Sandler decreased their target price on TransMedics Group from $160.00 to $120.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. Six equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $134.00.

TransMedics Group Stock Performance

Shares of TransMedics Group stock opened at $72.91 on Friday. The firm has a market cap of $2.52 billion, a P/E ratio of 16.57 and a beta of 1.91. The company has a current ratio of 6.74, a quick ratio of 6.19 and a debt-to-equity ratio of 1.70. TransMedics Group, Inc. has a 12 month low of $60.10 and a 12 month high of $156.00. The stock’s fifty day moving average price is $86.20 and its 200-day moving average price is $115.18.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $0.30 EPS for the quarter, missing the consensus estimate of $0.62 by ($0.32). The firm had revenue of $173.93 million for the quarter, compared to analysts’ expectations of $174.44 million. TransMedics Group had a net margin of 27.04% and a return on equity of 22.38%. The business’s quarterly revenue was up 21.2% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.70 EPS. On average, equities research analysts expect that TransMedics Group, Inc. will post 1.98 earnings per share for the current fiscal year.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.